18F-PSMA-1007和18F-胆PET/CT在前列腺癌患者与生化复发的比较:一个第三阶段,前性,多中心,随机化研究

相关实验视频

Updated: Jul 15, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Emmanouil Panagiotidis¹, Vasiliki Fragkiadaki², Nikolaos Papathanasiou³

¹Nuclear Medicine- PET/CT Department 'Theageneio' Cancer Center, Thessaloniki, .

Nuclear medicine communications

|October 2, 2023

概括

18F-PSMA-1007 PET/CT比18F-Choline PET/CT更有效地检测前列腺癌患者转移性病变的生物化学复发. 这项研究突出了PSMA的重点.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
放射性药理学是一种放射性药理学.

背景情况:

前列腺癌 (PCa) 管理依赖于准确的分期和复发的检测.
绝对治疗后的生化复发 (BCR) 需要对转移性病变进行敏感的成像.
已经使用了18F-Choline (FCH) PET/CT,但像18F-PSMA-1007 (PSMA) 这样的新型标记剂提供了潜在的改进.

研究的目的:

为了比较18F-PSMA-1007 PET/CT与18F-Choline PET/CT的诊断性能.
在前列腺癌和生化复发患者中评估这些成像方法的疗效.

主要方法:

一个前性的多中心随机交叉试验,涉及186名PCa和BCR患者.
患者在8天内随机顺序接受了PSMA和FCH PET/CT.
进行了至少6个月的随访,以评估诊断结果.

主要成果:

与18F-Choline PET/CT (69%) 相比,18F-PSMA-1007 PET/CT的检测率显著更高 (84%).
PSMA显示出更高的灵敏度 (0.8464对比0.6857) 和更好的检测在较低的PSA水平 (例如,61.8%对比39.5%在PSA≤1ng/mL).
在54.8%的患者中,PSMA有助于更准确的诊断,在这些患者中,成像改变了管理.

结论:

18F-PSMA-1007 PET/CT比18F-Choline PET/CT更有效地识别了BCR的前列腺癌患者的转移性病变.
在患者和区域层面上,PSMA PET/CT提供了更好的诊断准确性.
这一发现支持使用18F-PSMA-1007作为复发前列腺癌的首选成像剂.

更多相关视频

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring

Published on: November 13, 2012

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET